AnnJi Pharmaceutical Co., Ltd. (TPEX:7754)

Market Cap	3.76B
Revenue (ttm)	96.45M
Net Income (ttm)	-353.99M
Shares Out	93.88M
EPS (ttm)	-3.81
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	302,582
Average Volume	333,431
Open	39.95
Previous Close	40.10
Day's Range	39.90 - 41.00
52-Week Range	14.05 - 42.10
Beta	n/a
RSI	82.59
Earnings Date	Sep 22, 2025

About Splunk

AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy, a neurodegenerative disease; AJ202 for androgenetic alopecia; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammatory compound for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. AnnJi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7754

Financial Performance

In 2024, AnnJi Pharmaceutical's revenue was 96.45 million, a decrease of -32.80% compared to the previous year's 143.53 million. Losses were -353.99 million, 7.52% more than in 2023.